|
PARI Pharma Unveils
Closed System Using eFlow Technologyat Medical
Plastics Conference
MONTEREY, CALIFORNIA, OCTOBER 6, 2008 – Today,
PARI Pharma GmbH will unveil a prototype Closed
System using eFlow Technology that uses single
dose ampoules to control medication used in the
nebulizer system. By creating a proprietary,
unit-dose ampoule that is required to operate
the nebulizer, the Closed System using eFlow
Technology meets an unmet need by reducing the
risk of using the wrong medication in the
delivery device, simplifying filling procedures,
improving dose uniformity and hygiene.
“This is a very exciting period in inhalation
drug development. Building on our ability to
customize a delivery device and a medication
formulation, we have been able to take eFlow
Technology a step further by creating an aerosol
device that will only deliver its matching
formulation. This has a number of advantages for
our pharmaceutical partners, physicians, and
patients. The Closed System using eFlow
Technology takes away the risk of someone
putting anything other than their prescribed
medication into an advanced delivery device,
while keeping medication sealed until it is
opened in the nebulizer,” said Geoff A. Hunziker,
president of eFlow LLC. “As new device
technologies develop, it is critical for safety
and efficacy to ensure patients use the approved
delivery device for the inhaled drug.”
Thomas Gallem, director of product design of
PARI Pharma, will present “Development of a
closed, ampoule-based electronic nebulizer
system - next step in drug-device combination
for liquid aerosoltherapy” at the 22nd Annual
Medical Plastics Conference in Copenhagen,
Denmark today.
PARI Pharma is currently in discussions about
introducing the Closed System using eFlow
Technology into new clinical development
programs with pharmaceutical partners.
About eFlow Technology
eFlow Technology enables extremely efficient
aerosolization of liquid medications via a
vibrating, perforated membrane that includes
thousands of small holes that produce the
aerosol mist. Compared to other nebulization
technologies, eFlow Technology produces aerosols
with a very high density of active drug, a
precisely defined droplet size, and a high
proportion of respirable droplets delivered in
the shortest possible period of time. Combined
with its silent mode of operation, small size
(it fits in the palm of your hand), light
weight, and battery use, products incorporating
eFlow Technology reduce the burden of taking
daily, inhaled treatments. eFlow Technology and
products based on it are proprietary to PARI
Pharma.
PARI Pharma partners with pharmaceutical
companies to develop new or improved therapies
with eFlow Technology and other advanced
delivery platforms. Investigational eFlow
Nebulizer Systems areoptimized per
investigational drug product and are currently
in clinical trials for asthma, cystic fibrosis,
respiratory syncytial virus (RSV) infection, and
treatments for lung transplant patients among
other indications.
About PARI Pharma
PARI Pharma focuses on the development of
aerosol delivery devices and therapies. Based on
PARI’s100-year history working with aerosols,
PARI Pharma develops treatments for pulmonary
and nasal administration optimized with advanced
delivery technologies, such as eFlow Technology.
PARI Pharma provides comprehensive inhalation
drug development, including nebulizer
formulation development and optimization, CMC,
analytics, aerosol characterization, clinical
protocol development, and regulatory guidance.
PARI Pharma has several clinical development
programs ongoing, either partnered or on its
own. PARI Pharma, a PARI Medical Holding
company, is located in Munich, Germany with a
major presence in the United States. Online at
www.paripharma.com
Additional information on eFlow Technology is
available by contacting Kirsten Ayars at
805-452-7909 orGeoff A. Hunziker at
831-372-3580.
# # # |
